J Cardiovasc Interv.  2024 Jul;3(3):89-97. 10.54912/jci.2024.0004.

Protocol Update and Issues in EASTYLE Trial

• Kim MH
• Jeong YH

• KMID: 2561215
• DOI: http://doi.org/10.54912/jci.2024.0004

Abstract

The EASTYLE study is currently ongoing, based on the hypothesis that ticagrelor reduction and a 3-month aspirin removal strategy (Hybrid De-escalation) as part of the de-escalation strategy can reduce cardiovascular complications (net clinical outcome). There have been no previous studies on the reduction effect of ticagrelor, and this study involves 35 sites in Korea, showing a registration rate of around 20% currently. Registration is expected to close in early or mid 2025, and results are anticipated to be announced around the same time as the ELECTRA-SIRIO 2 study.

Keyword

Acute myocardial infarction; Bleeding; Ticagrelor; DAPT